CURIS INC
Close on Oct 19, 2026
- Market cap
- $815.06K
- P/E (TTM)
- –
- Dividend yield
- –
About Curis
Biological Products, (No Diagnostic Substances), SIC 2836
Curis, Inc. is a biotechnology company focused on the development of drug candidates for the treatment of cancer. The company's primary focus is emavusertib, an orally administered small molecule inhibitor targeting IRAK4 and FLT3 signaling pathways. Emavusertib is evaluated in clinical trials for hematologic malignancies, including primary central nervous system lymphoma and chronic lymphocytic leukemia. The company also holds licensed preclinical and clinical programs in immuno-oncology and precision oncology, developed through collaboration agreements. Its therapeutic candidates are primarily investigated for patients with rare or relapsed cancers.
The company operates in the biotechnology and clinical research sector with global development programs spanning the United States, Europe, and Asia, excluding retained partner territories. Curis maintains patent filings across the United States and international jurisdictions to protect its therapeutic assets. The company is headquartered in Lexington, Massachusetts.
Summary of the business section of Curis's latest annual report, written by StockData.
Company profile
Company
- Legal name
- CURIS INC
- Founded
- 2000
- Headquarters
- Lexington, MA
- Address
- 128 Spring Street, Building C, Suite 500 02421
- Phone
- (617) 503-6500
- Website
- curis.com
- Employees
- 24, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- CRIS
- Exchange
- Nasdaq
- Shares outstanding
- 2M, Aug 11, 2026
- Public float
- $24.80M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-20 reverse, Aug 14, 2026; 1-for-20 reverse, Jul 6, 2026; 1-for-20 reverse, Sep 28, 2023; 1-for-5 reverse, May 30, 2018; 1-for-5 reverse, May 29, 2018
- SEC CIK
- 1108205
- CUSIP
- 231269408
- ISIN
- US2312694084
- LEI
- 5299000YO6CX4WMFVX06
- EIN
- 04-3505116
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| James E. Dentzer | President & CEO, Director | 148,730 |
| Jonathan B. Zung | CDO | 66,667 |
| Diantha Duvall | CFO | 77,707 |
| Ahmed Hamdy MD | CMO | 66,667 |
| John Hohneker | Director | – |
| Martyn D. Greenacre | Director | 26,089 |
| Kenneth I. Kaitin | Director | 11,407 |
| Anne Elizabeth Borgman | Director | – |
| Marc Rubin | Director | 28,108 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $1.66M | $970.81K | $928.77K | $9 | – |
| FY2024 | $1.97M | $860.61K | $1.08M | $28 | – |
| FY2023 | $1.66M | $2.42M | $947.97K | $116 | – |
| FY2022 James E. Dentzer | $2.99M | $2.26M | $1.11M | $93 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of February 9, 2026, we had 24 employees, of which 20 are full-time.”
Corporate history
Events identified from SEC filings